Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor

Redic KA, Hough SM, Price EM

OncoTargets and Therapy 2016, 9:2783-2793

Published Date: 10 May 2016